AMGN Amgen Inc

Price (delayed)

$226.08

Market cap

$127.34B

P/E Ratio

23.14

Dividend/share

$7.04

EPS

$9.77

Enterprise value

$152.95B

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980. ...

Highlights
The revenue has grown by 3.1% year-on-year
AMGN's quick ratio is up by 38% since the previous quarter but it is down by 28% year-on-year
The P/E is 10% below the 5-year quarterly average of 25.7 but 9% above the last 4 quarters average of 21.3
Amgen's equity has decreased by 25% YoY
The net income has contracted by 24% YoY and by 2.4% from the previous quarter

Key stats

What are the main financial stats of AMGN
Market
Shares outstanding
563.27M
Market cap
$127.34B
Enterprise value
$152.95B
Valuations
Price to earnings (P/E)
23.14
Price to book (P/B)
15.62
Price to sales (P/S)
4.97
EV/EBIT
20.05
EV/EBITDA
13.85
EV/Sales
5.94
Earnings
Revenue
$25.77B
EBIT
$7.63B
EBITDA
$11.05B
Free cash flow
$7.84B
Per share
EPS
$9.77
Free cash flow per share
$13.83
Book value per share
$14.47
Revenue per share
$45.44
TBVPS
$62.91
Balance sheet
Total assets
$64.99B
Total liabilities
$56.78B
Debt
$37.58B
Equity
$8.22B
Working capital
$9.54B
Liquidity
Debt to equity
4.57
Current ratio
1.64
Quick ratio
1.19
Net debt/EBITDA
2.32
Margins
EBITDA margin
42.9%
Gross margin
75.4%
Net margin
21.8%
Operating margin
28.5%
Efficiency
Return on assets
9%
Return on equity
63.7%
Return on invested capital
16.9%
Return on capital employed
15.2%
Return on sales
29.6%
Dividend
Dividend yield
3.11%
DPS
$7.04
Payout ratio
72.1%

AMGN stock price

How has the Amgen stock price performed over time
Intraday
-0.72%
1 week
-3.94%
1 month
1.02%
1 year
-10.82%
YTD
0.49%
QTD
0.49%

Financial performance

How have Amgen's revenue and profit performed over time
Revenue
$25.77B
Gross profit
$19.43B
Operating income
$7.34B
Net income
$5.61B
Gross margin
75.4%
Net margin
21.8%
The net margin has declined by 26% year-on-year and by 3.1% since the previous quarter
The net income has contracted by 24% YoY and by 2.4% from the previous quarter
The company's operating margin fell by 22% YoY and by 2.1% QoQ
AMGN's operating income is down by 20% year-on-year

Growth

What is Amgen's growth rate over time

Valuation

What is Amgen stock price valuation
P/E
23.14
P/B
15.62
P/S
4.97
EV/EBIT
20.05
EV/EBITDA
13.85
EV/Sales
5.94
AMGN's EPS is down by 22% year-on-year
The P/E is 10% below the 5-year quarterly average of 25.7 but 9% above the last 4 quarters average of 21.3
The stock's price to book (P/B) is 49% more than its 5-year quarterly average of 10.5 and 2.1% more than its last 4 quarters average of 15.3
Amgen's equity has decreased by 25% YoY
The P/S is 8% less than the 5-year quarterly average of 5.4 and 6% less than the last 4 quarters average of 5.3
The revenue has grown by 3.1% year-on-year

Efficiency

How efficient is Amgen business performance
AMGN's return on assets is down by 23% year-on-year and by 2.2% since the previous quarter
The ROIC has contracted by 23% YoY
AMGN's return on sales is down by 22% year-on-year
The ROE has contracted by 12% YoY but it has grown by 5% from the previous quarter

Dividends

What is AMGN's dividend history
DPS
$7.04
Dividend yield
3.11%
Payout ratio
72.1%
Recent dividends

Financial health

How did Amgen financials performed over time
Amgen's total assets is 14% more than its total liabilities
AMGN's quick ratio is up by 38% since the previous quarter but it is down by 28% year-on-year
Amgen's current ratio has decreased by 28% YoY but it has increased by 25% from the previous quarter
AMGN's debt to equity is up by 46% YoY and by 15% QoQ
Amgen's equity has decreased by 25% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.